LIVE POLIO IRUS VACCINES

Index
613
Dosage-continued
statistics, USSR, 418
trivalent vaccine, optimum levels, 121
"Double blind study"
need for, 157
no knowledge of vaccine or placebo, 461, 462
Douglas, GQrdon W., 321
DPT inoculation, 328, 597-598
Dragée-candy, 241, 264, 414
advantages, 419, 577, 585
Drobyshevskaya, A. I., paper, 482-501
Drozdov, S. G., paper 413-428; 416
Duben, J., paper 228-239
Dulbecco method
plaque technique, 34
Dulbecco, Renato, 5, 7, 47, 49-50, 109-110, 268, 328-
329, 480, 505, 574
Dulutlh
mass trial, 21,000 participants, 461
DuPan, R. Martin, 322, 323
Dyes
photodynamic action, destruction of B virus, 87
Dysentery
carrier vs. disseminator, 410
Dzagurov, S. G., paper, 413-428
E 206, see Poliomyelitis virus, Type 1, E 206
E marker, see Elution marker
Earle's solution, 125, 229
East Germany, see German Democratic Republic
Eastern equine encephalitis vaccine
effectiveness when antiserum is added, 329
ECHO virases, 241, 246
isolation from suspected polio cases, 571
occurrence, 421, 537
ECHO 1
antiserum added to fecal suspensions before
poliovirus isolation, 203
ECHO 1-14
identified, 271
ECHO 2, 14
in 7 unvaccinated infants, 273
ECHO 7, 8, 12, 14
isolated, Costa Rica, 575
ECHO 7, 14, 19
restricted to Franklin, Louisiana, 151
ECHO 8, 257
effect on spread of vaccine, 263
ECHO 10
similar to SA-III, 86
ECHO 12
interference, 181
ECHO 14, 19
restricted to Morgan City, Louisiana, 151
ECMO viruses, see Simian viruses
Ecological behlavior, described, 110, 603
Economic conditions, see Socio-economic conditions
Effectiveness
analysis depends on triple negatives, 373, 444
and change in markers, 7
calculation on basis of all cases, 481
Cincinnati, Ohio, 591
controls selection, important in evaluating, 506
Effectiveness-continued
criterion, 4, 371, 568, 579, 602
difference between number of expected and observed
cases, 401
four Soviet republics, 497
high degree, 577
immunological and epidemiological, 482-501
Leopoldville, Congo, 466-473
long-range, determination, 445
Netherlands, 143
radical breakdowns in seasonal rise in polio, 493
related to interval between doses, 116
trivalent vaccine in young children, 113-120
Eiger, Marvin S., paper, 315-321
Eklund, C. M., 459, 462
Electrostal, USSR, 242
Elution marker
differential adsorption on cellulose columns, 13
method detailed, 42, 43
Embil, Juan, paper 330-340, 365-370; 330
Embu district, Kenya, 479
EMC virus, possible contaminant, 474
Encephalitis
in 9-year-old vaccinee, 593
incidence through trial period, 454
End point technique
not sensitive enough, 237
Endanmoeba coli, Cuban children infested, 368
Endemic areas, Japan
infants immunized with Salk, 191
Enders, J. F., 5
Endocrine factor
susceptibility after birth enhanced, 300
England
maternal antibody half-life study, 294
Type 3 specimens, 124
Enjoji, Dr.- (of Fukuoka University), 193
Enteroviruses
and response to vaccination, 122, 179, 271, 274
clinical manifestations, 157
dissemination of, 411
86 episodes, 150
from sewage samples, a study, 439
identified in stools, 273, 368, 439
incidence compared with polioviruses, 380
interference, 8, 378, 394, 429, 575, 602
isolation, 400, 570, 591
Louisiana study, tabulated, 152, 153
prevalence among children, 182, 243
search in monkey kidney and human cell line, 123
Environment
relation to results, 121
subtropical and polio, 184
Epidemics
Aland archipelago, 1953, 536
and opponents of live virus vaccine, 8
Costa Rica, 1954, 561, 569, 575
Des Moines
specific attack rates by dose and socio-economic
class, 375
evolution, Nicaragua, 1959-60, 559
Hungary, 1959, 518
in lower economic groups, 158